Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis
Background:Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited.Aims:Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database.Methods:A large therapeutic...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 5, 2021
|
| In: |
Journal of psychopharmacology
Year: 2021, Jahrgang: 35, Heft: 3, Pages: 273-278 |
| ISSN: | 1461-7285 |
| DOI: | 10.1177/0269881120985166 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/0269881120985166
|
| Verfasserangaben: | Maxim Kuzin, Ekkehard Haen, Christoph Hiemke, Benjamin Bochon, Karolina Bochon, Gerhard Gründer, Michael Paulzen and Georgios Schoretsanitis |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1766795692 | ||
| 003 | DE-627 | ||
| 005 | 20230427034931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210813s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0269881120985166 |2 doi | |
| 035 | |a (DE-627)1766795692 | ||
| 035 | |a (DE-599)KXP1766795692 | ||
| 035 | |a (OCoLC)1341420530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kuzin, Maxim |d 1985- |e VerfasserIn |0 (DE-588)1154710564 |0 (DE-627)1016112300 |0 (DE-576)501187200 |4 aut | |
| 245 | 1 | 0 | |a Body mass index as a determinant of clozapine plasma concentrations |b a pharmacokinetic-based hypothesis |c Maxim Kuzin, Ekkehard Haen, Christoph Hiemke, Benjamin Bochon, Karolina Bochon, Gerhard Gründer, Michael Paulzen and Georgios Schoretsanitis |
| 264 | 1 | |c February 5, 2021 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.08.2021 | ||
| 520 | |a Background:Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited.Aims:Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database.Methods:A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20?30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ?30?kg/m2, n=162) and with low body mass index values (CLZlow, body mass index <20?kg/m2, n=27). Comparisons of plasma and dose-adjusted plasma concentrations (C/D) of clozapine were based on the Spearman?s correlation (rs), Kruskal Wallis and Mann-Whitney-U tests. For percentages we used the Pearson chi-square test (?2). To assess effects of confounders we used bootstrapping analysis of covariates.Results/outcomes:Regarding demographic characteristics, groups differed only for sex percentage with more females than males in CLZlow and CLZhigh compared to CLZ0 (p=0.001 for ?2 test). Plasma and C/D values were positively associated with body mass index (rs=0.108, p=0.022 and rs=0.156, p=0.001 respectively). Intergroup differences were observed for plasma and dose-adjusted concentrations of clozapine (p=0.031 and p=0.029 for Kruskal Wallis respectively): post-hoc pairwise comparisons showed higher plasma concentrations and C/D of clozapine in CLZhigh compared to CLZ0 (p=0.014 and p=0.007 respectively for Mann-Whitney U-test), by mean 21 and 18%, respectively. Differences for C/D values remained after accounting for sex (p=0.02).Conclusions/interpretation:In obese patients, bioavailability, distribution or elimination of clozapine may be altered due to increased clozapine deposits in fat tissue and hepatic enzyme activity changes. | ||
| 650 | 4 | |a body mass index | |
| 650 | 4 | |a clozapine | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a Therapeutic drug monitoring | |
| 700 | 1 | |a Haen, Ekkehard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hiemke, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bochon, Benjamin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bochon, Karolina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gründer, Gerhard |e VerfasserIn |0 (DE-588)1078251037 |0 (DE-627)838195350 |0 (DE-576)449927644 |4 aut | |
| 700 | 1 | |a Paulzen, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoretsanitis, Georgios |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of psychopharmacology |d London [u.a.] : Sage, 1987 |g 35(2021), 3, Seite 273-278 |h Online-Ressource |w (DE-627)324614942 |w (DE-600)2028926-1 |w (DE-576)276556313 |x 1461-7285 |7 nnas |a Body mass index as a determinant of clozapine plasma concentrations a pharmacokinetic-based hypothesis |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:3 |g pages:273-278 |g extent:6 |a Body mass index as a determinant of clozapine plasma concentrations a pharmacokinetic-based hypothesis |
| 856 | 4 | 0 | |u https://doi.org/10.1177/0269881120985166 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210813 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1078251037 |a Gründer, Gerhard |m 1078251037:Gründer, Gerhard |d 60000 |e 60000PG1078251037 |k 0/60000/ | ||
| 999 | |a KXP-PPN1766795692 |e 3968039491 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Maxim Kuzin, Ekkehard Haen, Christoph Hiemke, Benjamin Bochon, Karolina Bochon, Gerhard Gründer, Michael Paulzen and Georgios Schoretsanitis"]},"person":[{"family":"Kuzin","given":"Maxim","role":"aut","display":"Kuzin, Maxim"},{"family":"Haen","given":"Ekkehard","role":"aut","display":"Haen, Ekkehard"},{"display":"Hiemke, Christoph","role":"aut","given":"Christoph","family":"Hiemke"},{"display":"Bochon, Benjamin","given":"Benjamin","role":"aut","family":"Bochon"},{"role":"aut","given":"Karolina","display":"Bochon, Karolina","family":"Bochon"},{"family":"Gründer","display":"Gründer, Gerhard","role":"aut","given":"Gerhard"},{"family":"Paulzen","display":"Paulzen, Michael","role":"aut","given":"Michael"},{"family":"Schoretsanitis","display":"Schoretsanitis, Georgios","given":"Georgios","role":"aut"}],"recId":"1766795692","origin":[{"dateIssuedKey":"2021","dateIssuedDisp":" February 5, 2021"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1766795692"],"doi":["10.1177/0269881120985166"]},"physDesc":[{"extent":"6 S."}],"relHost":[{"title":[{"title_sort":"Journal of psychopharmacology","subtitle":"the official journal of the British Association for Psychopharmacology","title":"Journal of psychopharmacology"}],"part":{"volume":"35","year":"2021","text":"35(2021), 3, Seite 273-278","extent":"6","pages":"273-278","issue":"3"},"language":["eng"],"pubHistory":["1.1987 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Sage","dateIssuedDisp":"1987-","dateIssuedKey":"1987","publisherPlace":"London [u.a.]"}],"recId":"324614942","id":{"issn":["1461-7285"],"zdb":["2028926-1"],"eki":["324614942"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Body mass index as a determinant of clozapine plasma concentrations a pharmacokinetic-based hypothesisJournal of psychopharmacology","note":["Gesehen am 24.11.04"]}],"note":["Gesehen am 13.08.2021"],"title":[{"subtitle":"a pharmacokinetic-based hypothesis","title":"Body mass index as a determinant of clozapine plasma concentrations","title_sort":"Body mass index as a determinant of clozapine plasma concentrations"}],"language":["eng"]} | ||
| SRT | |a KUZINMAXIMBODYMASSIN5202 | ||